MannKind to Current at 2024 Cantor Fitzgerald World Healthcare Convention – MannKind (NASDAQ:MNKD)

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) — MannKind Company MNKD, an organization targeted on the event and commercialization of progressive inhaled therapeutic merchandise and gadgets for sufferers with endocrine and orphan lung ailments, introduced at this time that Chief Monetary Officer Chris Prentiss and Dr. Wasim Fares Therapeutic Space Head, Orphan Lung Illnesses, will share updates throughout a hearth chat on the 2024 Cantor Fitzgerald World Healthcare Convention in New York.

The hearth chat will happen on Wednesday, September 18 starting at 1:20 p.m. Jap Time. A hyperlink to the dwell audio webcast of the session shall be obtainable on MannKind Company’s web site at: https://investors.mannkindcorp.com/events-and-presentations. An archived, recorded model can even be obtainable on the web site for roughly 30 days following the convention.

About MannKind
MannKind Company MNKD focuses on the event and commercialization of progressive inhaled therapeutic merchandise and gadgets to handle severe unmet medical wants for these dwelling with endocrine and orphan lung ailments.

We’re dedicated to utilizing our formulation capabilities and system engineering prowess to minimize the burden of ailments akin to diabetes, nontuberculous mycobacterial (NTM) lung illness, pulmonary fibrosis, and pulmonary hypertension. Our signature applied sciences – dry-powder formulations and inhalation gadgets – provide fast and handy supply of medicines to the deep lung the place they’ll exert an impact regionally or enter the systemic circulation, relying on the goal indication.

With a passionate crew of Mannitarians collaborating nationwide, we’re on a mission to offer folks management of their well being and the liberty to dwell life.

Please go to mannkindcorp.com to study extra, and comply with us on LinkedIn, Facebook, X or Instagram.

MANNKIND is a registered trademark of MannKind Company.

For MannKind:
Christie Iacangelo
Company Communications
(818) 292-3500
E-mail: [email protected]

Investor Relations
(818) 661-5000
E-mail: [email protected]